OBJECTIVES: To assess the outcomes of the Loozit adolescent weight management intervention and to evaluate the effect of additional therapeutic contact 12 months into the program. DESIGN: A 24-month, 2-arm randomized controlled trial. Results at 12 months are presented. SETTING:Community health center and children's hospital in Sydney, Australia. PARTICIPANTS: A total of 151 overweight or obese 13- to 16-year-olds. INTERVENTION: In the first 2 months (phase 1), participants received 7 adolescent and parent weekly sessions focused on lifestyle modification. From 2 to 24 months (phase 2), adolescents attended booster sessions once every 3 months. During phase 2, adolescents randomized to the additional therapeutic contact arm also received telephone coaching and electronic communications once every 2 weeks. OUTCOME MEASURES: Baseline to 12-month changes in body mass index z score and waist to height ratio (primary outcomes) and changes in metabolic, psychosocial, and behavioral variables. RESULTS: Of 151 randomized adolescents, 82.1% completed 12-month follow-up. Intent-to-treat analyses showed significant reductions in mean body mass index z score (-0.09; 95% CI, -0.12 to -0.06), waist to height ratio (-0.02; 95% CI, -0.03 to -0.01), total cholesterol level (-4 mg/dL; 95% CI, -8 to 0 mg/dL; to convert to millimoles per liter, multiply by 0.0259), and triglycerides level (geometric mean, -80 mg/dL; 95% CI, -88 to -71 mg/dL; to convert to millimoles per liter, multiply by 0.0113). Most psychosocial outcomes improved, including global self-worth, but there were few dietary, physical activity, or sedentary behavior changes. No difference was found in primary outcomes between participants who did or did not receive additional therapeutic contact. CONCLUSIONS: The Loozit randomized controlled trial produced a significant but modest reduction in body mass index z score and improved psychosocial outcomes at 12 months. Supplementary telephone and electronic contact provided no additional benefit at 12 months. Trial Registration anzctr.org.au Identifier: 12606000175572.
RCT Entities:
OBJECTIVES: To assess the outcomes of the Loozit adolescent weight management intervention and to evaluate the effect of additional therapeutic contact 12 months into the program. DESIGN: A 24-month, 2-arm randomized controlled trial. Results at 12 months are presented. SETTING: Community health center and children's hospital in Sydney, Australia. PARTICIPANTS: A total of 151 overweight or obese 13- to 16-year-olds. INTERVENTION: In the first 2 months (phase 1), participants received 7 adolescent and parent weekly sessions focused on lifestyle modification. From 2 to 24 months (phase 2), adolescents attended booster sessions once every 3 months. During phase 2, adolescents randomized to the additional therapeutic contact arm also received telephone coaching and electronic communications once every 2 weeks. OUTCOME MEASURES: Baseline to 12-month changes in body mass index z score and waist to height ratio (primary outcomes) and changes in metabolic, psychosocial, and behavioral variables. RESULTS: Of 151 randomized adolescents, 82.1% completed 12-month follow-up. Intent-to-treat analyses showed significant reductions in mean body mass index z score (-0.09; 95% CI, -0.12 to -0.06), waist to height ratio (-0.02; 95% CI, -0.03 to -0.01), total cholesterol level (-4 mg/dL; 95% CI, -8 to 0 mg/dL; to convert to millimoles per liter, multiply by 0.0259), and triglycerides level (geometric mean, -80 mg/dL; 95% CI, -88 to -71 mg/dL; to convert to millimoles per liter, multiply by 0.0113). Most psychosocial outcomes improved, including global self-worth, but there were few dietary, physical activity, or sedentary behavior changes. No difference was found in primary outcomes between participants who did or did not receive additional therapeutic contact. CONCLUSIONS: The Loozit randomized controlled trial produced a significant but modest reduction in body mass index z score and improved psychosocial outcomes at 12 months. Supplementary telephone and electronic contact provided no additional benefit at 12 months. Trial Registration anzctr.org.au Identifier: 12606000175572.
Authors: David A Fedele; Christopher C Cushing; Alyssa Fritz; Christina M Amaro; Adrian Ortega Journal: JAMA Pediatr Date: 2017-05-01 Impact factor: 16.193
Authors: Elissa Jelalian; E Whitney Evans; Diana Rancourt; Lisa Ranzenhofer; Neta Taylor; Chantelle Hart; Ronald Seifer; Kelly Klinepier; Gary D Foster Journal: Child Obes Date: 2019-12-18 Impact factor: 2.992
Authors: Raquel de Melo Boff; Ronald Patrick Araujo Liboni; Igor Pacheco de Azevedo Batista; Lauren Heineck de Souza; Margareth da Silva Oliveira Journal: Eat Weight Disord Date: 2016-08-19 Impact factor: 4.652
Authors: Kevin Patrick; Gregory J Norman; Evelyn P Davila; Karen J Calfas; Fred Raab; Michael Gottschalk; James F Sallis; Suni Godbole; Jennifer R Covin Journal: J Diabetes Sci Technol Date: 2013-05-01
Authors: Leon M Straker; Kyla L Smith; Ashley A Fenner; Deborah A Kerr; Alexandra McManus; Melissa C Davis; Angela M Fielding; Tim S Olds; Martin S Hagger; Anne J Smith; Rebecca A Abbott Journal: BMC Public Health Date: 2012-06-21 Impact factor: 3.295
Authors: Lena Al-Khudairy; Emma Loveman; Jill L Colquitt; Emma Mead; Rebecca E Johnson; Hannah Fraser; Joan Olajide; Marie Murphy; Rochelle Marian Velho; Claire O'Malley; Liane B Azevedo; Louisa J Ells; Maria-Inti Metzendorf; Karen Rees Journal: Cochrane Database Syst Rev Date: 2017-06-22